Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia

Continued use of evolocumab added to SOC in patients with HeFH yields persistent and marked low-density lipoprotein cholesterol reductions during 48 weeks of follow-up. Long-term dosing of evolocumab with SOC was safe and well tolerated.